Clinical trials: Hepatitis C, completed
Chronic Hepatitis b
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
- Trial name
- NCT04980482
- Testing
- AB-729, Peg-IFNα-2a
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, Hepatitis C
Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants
The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States (US) is relatively low. However, immigrant populations in the US from Asia and sub-Saharan Africa have substantially higher prevalence…
- Conditions
- Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
- Trial name
- NCT02366286
- Where
- United States
- Volunteers
- 892 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hepatitis B, Chronic
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Trial name
- MARCH (NCT04856085)
- Testing
- VIR-2218, VIR-3434, PEG-IFNα
- Where
- 37 sites in United States, Canada and 10 more
- Volunteers
- 244 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Viral Hepatitis, Hepatitis B Infection
Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
This study explores how psychosocial factors (e.g., chronic stress, depression) may lead to liver disease progression such as liver cirrhosis or liver cancer among Korean American chronic hepatitis B infection patients.
- Trial name
- NCT05117541
- Testing
- Interview, Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- Thomas Jefferson University
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Background: The COVID-19 global pandemic killed more than 6 million people worldwide. Several vaccines have been developed against the virus that causes this disease.
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD
- Trial name
- NCT05669677
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability…
- Trial name
- NCT04412863
- Testing
- VIR-2218, pegylated interferon-alfa 2a
- Where
- 22 sites in Australia, Hong Kong and 4 more
- Volunteers
- 84 people
- Sponsor
- Vir Biotechnology, Inc.
Hepatitis C, Chronic
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients.
- Trial name
- Fibrosar (NCT00265642)
- Testing
- Irbesartan
- Where
- France
- Volunteers
- 166 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C Virus Genotype 4 Infection
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Success rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard treatment, are disappointing.
- Trial name
- NCT02107365
- Testing
- Asunaprevir, Daclatasvir, Ribavirin
- Where
- 25 sites in France
- Volunteers
- 60 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Chronic, Hepatocellular Carcinoma
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
- Trial name
- FRI-STC (NCT02771405)
- Testing
- Sofosbuvir, Ribavirin, Simeprevir
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- National Hepatology & Tropical Medicine Research Institute
Hepatitis C Viral
Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV
The aim of this study is to conduct an evaluation of hepatitis C treatments in NHS Tayside in order to empirically test the "treatment as prevention" models.
- Trial name
- ERAPID HCV (NCT03356405)
- Where
- United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- University of Dundee
Hepatitis C Virus Infection, Response to Therapy of
Rapid HCV Treatment Access for Persons Who Use Drugs
This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP).
- Trial name
- RAPID-HCV (NCT04677153)
- Testing
- Test and treat plus peer mentors, Usual care
- Where
- 4 sites in United States, Canada
- Volunteers
- 198 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis b
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects.
- Trial name
- NCT05960240
- Testing
- AB-101, Nucleos(t)ide Analogue
- Where
- 10 sites in Hong Kong, Italy and 5 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, HIV Infection
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer.
- Trial name
- B-BOOST (NCT00670839)
- Testing
- GenHevac-B
- Where
- France
- Volunteers
- 178 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV Infection, Liver Cirrhosis, Experimental
Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation
Evaluation of efficacy of triple therapy with pegylated interferon, ribavirin, and boceprevir in patients with genotype 1 chronic hepatitis C, who are treatment-naive, have relapsed, or are non-responders with cirrhosis and…
- Trial name
- NCT01463956
- Testing
- Boceprevir, Peg-Interferon α-2b or Peg-Interferon α-2a, Ribavirin
- Where
- 19 sites in France
- Volunteers
- 58 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
Hepatitis
ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV
The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.
- Trial name
- ETOC (NCT00901524)
- Testing
- Peg-interféron alpha 2a + ribavirin
- Where
- France
- Volunteers
- 58 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders
Vitamin D deficiency is commonly found in patients with chronic hepatitis C. The investigators hypothesize that the correction of hypovitaminosis D before the initiation of anti-HCV combination therapy and the maintenance of an…
- Trial name
- ANRS VITAVIC (NCT01226446)
- Testing
- vitamin D
- Where
- France
- Volunteers
- 32 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Carcinoma, Hepatocellular, Hepatitis, Viral, Human
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer…
- Trial name
- Lipiocis (NCT00116454)
- Testing
- 131 I-lipiodol
- Where
- France
- Volunteers
- 73 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis B
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The purpose of this study is to determine if DNA vaccination of chronic HBV patients under treatment with NRTI can restore T-cell responsiveness and delay virologic reactivation after treatment discontinuation.
- Trial name
- VAC-ADN (NCT00536627)
- Testing
- DNA vaccine pCMVS2.S
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis